Logo
x

Search

Subscribe Now

Metastatic

Junshi Reports NMPA's Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Junshi Reports NMPA's Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell...

  • July 30, 2021
BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or...

  • June 4, 2021
The US FDA Grants Priority Review to Takeda's Mobocertinib (TAK-788) for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer

The US FDA Grants Priority Review to Takeda's Mobocertinib (TAK-788) for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Can...

  • April 28, 2021
Astellas and Seagen Report the US FDA's Acceptance of Two sBLA for Padcev (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Astellas and Seagen Report the US FDA's Acceptance of Two sBLA for Padcev (enfortumab vedotin) in Locally Advanced or Metastatic U...

  • April 20, 2021
Roche's Tecentriq Receives CHMP's Positive Opinion for 1L Treatment for Metastatic Non-Small Cell Lung Cancer

Roche's Tecentriq Receives CHMP's Positive Opinion for 1L Treatment for Metastatic Non-Small Cell Lung Cancer

  • March 29, 2021
Astellas and Seagen Report EMA's Acceptance of MAA for Enfortumab Vedotin to Treat Locally Advanced or Metastatic Urothelial Cancer

Astellas and Seagen Report EMA's Acceptance of MAA for Enfortumab Vedotin to Treat Locally Advanced or Metastatic Urothelial Cance...

  • March 26, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.